China's Giant Land-Based Carrier Mockup Grows In Size, Now Resembles Ford Class
China's full-size, land-based aircraft carrier test facility, a key part of the country's path toward establishing a carrier fleet and associated air wings, is being modified once again, and this time in a massive way. The extensive reworking and expansion of the unique facility suggests that the aircraft carrier mockup is now intended to represent a layout similar to the U.S. Navy's Ford class. This likely coincides with the configuration of China's next, more advanced, homegrown carrier design.
A satellite photo of the land-based aircraft carrier mockup in Wuhan, taken on April 6, shows the changes that have taken place, including a much greater overall flight-deck width, and the island superstructure redesigned and much moved further aft, as on the Ford class. So significant is the extra width, meanwhile, that the edges of the deck now extend out to or even over the adjacent road.
The primary role of the aircraft carrier mockup is to evaluate different aircraft designs for potential use at sea, including how they will fit and be moved around on the carrier's deck. It should also be noted that the structure sits atop a building, something not immediately obvious from satellite imagery.
On the deck in the latest image are mockups of various aircraft, although these are covered with tarpaulins or some other material, making it hard to identify them definitively. At least one of the mockups is a J-15 Flanker series carrier-based fighter, while another looks to be a J-35 carrier-based stealth fighter, and another a KJ-600 carrier-based airborne early warning and control (AEW&C) aircraft. Mockups of this kind are frequently used in carrier development work in China, both on land and at sea.
So far the best and clearest images of the KJ-600 carrierborne AEW mock up ontop the carrier test facility in Wuhan.(Via LKJ86 / PDF) pic.twitter.com/9WdF59N6Km
— @Rupprecht_A (@RupprechtDeino) April 12, 2019
In the past, an apparent mockup of China's stealthy GJ-11 Sharp Sword unmanned combat aerial vehicle (UCAV) has also appeared aboard the land-based carrier mockup, as you can read about here.
Via ACuriousPLAFan/SDF:
Supposedly not a recent image, but still the carrier mock-up and test facility at Wuhan has gained some new aircraft: Visible now are clearly mock-ups of J-15, J-35, KJ-600 and a GJ-11H on the flight deck.(Image via @伏尔戈星图 from Weibo) pic.twitter.com/UL6uk81zh4
— @Rupprecht_A (@RupprechtDeino) December 19, 2023
Work with radio emissions and other testing is also done at the facility.
When it first appeared, the full-size aircraft carrier mockup broadly replicated the design of the Type 001 and Type 002 carriers.
The Type 001 Liaoning (CV-16), the first vessel of this type to be operated by the People's Liberation Army Navy (PLAN), was acquired from Ukraine as an incomplete Soviet Kuznetsov class ship, the Varyag. The next PLAN carrier to enter service, the Type 002 Shandong (CV-17), was built in China but was still modeled closely on the Type 001.
Subsequently, Wuhan's aircraft carrier mock-up was modified to better resemble China's next carrier, the Type 003 Fujian (CV-18). This introduced a different configuration, with no bow takeoff ramp. Instead, the Type 003 marks the PLAN's switch to catapult-assisted takeoff but arrested recovery, or CATOBAR, operations.
Now, it seems, the facility is being prepared for tests of China's next-generation aircraft carrier, generally referred to as the Type 004. At the same time, the remodeling should also provide a better representation of the Fujian, a vessel that is still undergoing pre-service trials.
In fact, the new Type 004 carrier may well already be under construction.
In February of this year, TWZ reported on how construction work at a shipyard in Dalian, seen in satellite imagery dating back to May 2024, revealed a module consistent with an aircraft carrier — or otherwise related to the testing of such a vessel.
Based on this module, it appears likely that the Type 004 will be loosely modeled after the Ford class, at least in terms of having two waist catapults, in addition to the two bow catapults. This will provide an extra catapult compared with the Fujian, which has a single catapult in the waist position.
In the past, a Ford-style design also appeared in concept art from the Jiangnan Shipyard in Shanghai. The carrier shown in that artwork had some broad external similarities with the Ford, as well as with France's future New Generation Aircraft Carrier. However, not too much should be read into this, especially since it appears that the Type 004 might now be under construction in Dalian, rather than in Shanghai. Still, the appearance of a superstructure far to the rear on the Wuhan mockup is indicative that this design element could appear on the Type 004.
Whatever the final configuration of the Type 004 — and, at this early stage, we really don't know for sure — previous suggestions hinted that the new carrier could enter service sometime in the late 2020s.
The Type 004 is expected to be a more advanced design than its predecessors, including the Fujian, the country's first truly domestically designed and produced carrier, which is still preparing for operational service.
Like the Fujian, the Type 004 will be equipped to launch aircraft via catapults. This is in contrast to the PLAN's two previous carriers — the Shandong and the Liaoning, which are both short takeoff but arrested recovery, or STOBAR, types with prominent 'ski jump' takeoff ramps.
As we have discussed in the past, catapults offer many advantages over STOBAR, especially when it comes to launching aircraft at higher gross weights, which translates to larger fuel and ordnance loads. They can also generally accommodate a wider array of aircraft types, too. This includes larger and slower designs, like the KJ-600 AEW&C aircraft, as well as smaller ones, such as drones.
It's assumed that the Type 004 will use an advanced electromagnetic aircraft launch system (EMALS), provided it proves to be successful on the Fujian. Otherwise, this type of equipment is currently only in use with the U.S. Navy.
Other new developments for the Type 004 will address its air wing, which is expected to host various drones, such as navalized versions of the GJ-11 Sharp Sword UCAV. These will be in addition to the aforementioned KJ-600, various different advanced versions of the J-15, and the J-35, plus helicopters.
Less clear is what type of propulsion the Type 004 will use, although there have been repeated reports that it will be a nuclear-powered vessel. This would be a first for a PLAN carrier and would guarantee an effectively unlimited range, as well as help meet the power-generation demands of ever-improving sensors and other mission systems.
In its most recent assessment of Chinese military power, the Pentagon doesn't explicitly mention the Type 004, but does state that the PLAN is 'in the beginning stages of operating its multi-carrier force.' It also notes that the Fujian is just the first warship within a 'next generation of carriers' that will be characterized by 'greater endurance and an electromagnetic catapult launch system, making them capable of launching various types of specialized fixed-wing aircraft for missions, such as airborne early warning and electronic warfare. This will increase the striking power of a potential PLAN carrier battle group when deployed to areas beyond the PRC's immediate periphery.'
At this point, we cannot be certain that the module seen under construction at Dalian is indeed made to resemble the Type 004, although it seems likely. However, this development, as well as the changes to the land-based aircraft carrier mockup in Wuhan, certainly point to activities related to China's next domestically produced carrier design are accelerating.
Contact the author: thomas@thewarzone.com

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 hours ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@
Yahoo
17 hours ago
- Yahoo
FDA meeting gives window into gene therapy field's angst
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Anyone looking for evidence of genetic medicine's enormous promise need only read of KJ Muldoon. The 10-month-old infant headed home from a Philadelphia hospital this week, dressed in a celebratory cap and gown, after his life-threatening disease was successfully treated with a bespoke CRISPR therapy. While baby KJ is not cured, the treatment has stabilized his disease, a rare liver condition known as CSP1 deficiency, to such extent he's able to resume eating a normal diet. Doctors, who hurriedly designed and constructed KJ's custom therapy in a matter of months, have backed off supportive medications and hope he'll no longer need a liver transplant. 'Each year, 10 million babies are born with one of about 10,000 known rare genetic diseases, many of which are, in principle, now treatable with genetic medicines,' David Liu, a pioneering CRISPR scientist whose laboratory helped in KJ's treatment, said at a meeting hosted by the Food and Drug Administration Thursday. 'The opportunity created by this perfect storm moment in scientific, medical, regulatory and manufacturing innovation is to provide on-demand genetic treatments like KJ's at scale.' Yet Liu and 22 other gene therapy experts and advocates who attended Thursday's roundtable didn't travel to the regulator's headquarters in White Oak, Maryland to extol the field's advances. By and large, they came to warn of a crisis. There are now dozens of approved cell and gene therapies in the U.S., some of which offer near-curative potential for serious diseases like spinal muscular atrophy, sickle cell disease and acute lymphoblastic leukemia. However, the sector that's produced these therapies is struggling. Investors have soured on genetic medicine as developers struggle to prove they can profitably sell the complex and often hugely expensive treatments. Biotechnology companies are cutting research, laying off staff and, in some cases, shutting down. Large pharmaceutical firms are no longer willing to bet billions of dollars they can surmount the regulatory and reimbursement hurdles that stand in the way of many of these therapies. And academic labs, still bursting with promising new ideas for technologies like CRISPR, now fear their projects will wither on the vine. 'We estimate that over 100 rare disease gene therapy products that had reached clinical stage have been discontinued since 2023 — not because of treatment failure, but because of the risk of market failure,' said Terence Flotte, dean of the University of Massachusetts' T.H. Chan School of Medicine and president of the American Society of Cell and Gene Therapy. 'The scientific advances that we have witnessed are just nothing short of spectacular. It's not hyperbole,' said Crystal Mackall, a professor at Stanford University and founding director of the cancer cell therapy center there. 'Despite this unconditional scientific success, the field is really struggling to deliver these therapies to all patients who can benefit.' Their warnings found a receptive audience in FDA leadership. Commissioner Martin Makary and top official Vinay Prasad, who leads the office that oversees cell and gene therapies, were sympathetic to experts' arguments and pledged to help. 'We are going to continue the successes of the FDA in facilitating the regulatory process for these conditions and these products,' said Makary. 'We're also going to try to improve by creating more efficiencies.' Prasad, who in the past has criticized the FDA's accelerated approval of a gene therapy for Duchenne muscular dystrophy, showed support for flexible trial designs and endpoints when appropriate for the disease or treatment. He also noted the agency accepts that cell and gene therapies don't always comes with transformative potential. 'We understand that progress is not always made in a single leap,' he added. 'We will consider incremental steps forward, because those add up.' The assembled experts came with lists of possible solutions. Carl June, a famed immunologist and cell therapy researcher at the University of Pennsylvania, called for the U.S. to borrow from the two-tier regulatory system used in China, which allows for medical institutions to more rapidly start first-in-human trials under the supervision of local review boards. Don Kohn, a University of California, Los Angeles scientist who has developed gene therapies, asked the FDA to reduce the requirements for 'comparability' testing when companies transition production from academic to commercial settings. Others emphasized the importance of regulatory awards, like the priority review vouchers granted by the FDA to developers of certain therapies, who often sell them for needed capital. And many called for the agency to share more feedback and lessons learned from the applications they receive from industry. Behind all of their suggestions was a consistent concern: If regulators don't help solve the field's problems, the U.S. risks losing its leadership in developing the kinds of treatments that can cure diseases. 'If we don't adapt, the next generation of treatments will emerge abroad,' said June. 'The future of medicine with cell and gene therapy is at stake.' Their message seemed to be heard by Makary and Prasad, who noted that many of the issues raised are on their radar at FDA. Prasad, for instance, noted that they hope to redact and make available more internal documents to aid developers' understanding of what the FDA is looking for. 'This is not a horse and pony show to say we did this,' added Makary. 'This is an honest listening session.' Recommended Reading A bespoke CRISPR therapy suggests a blueprint for treating 'N-of-1' diseases